Clinical trials: Emphysema, Pulmonary
Biliary Atresia, Alagille Syndrome
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
Noninvasive monitoring of liver fibrosis is an unmet need within the clinical management of pediatric chronic liver disease. While liver biopsy is often used in the initial diagnostic evaluation, subsequent biopsies are rarely…
- Conditions
- Biliary Atresia, Alagille Syndrome, Alpha1 Anti-Trypsin Deficiency, Portal Hypertension
- Trial name
- FORCE (NCT02922751)
- Testing
- Liver Stiffness Measurement (LSM)
- Where
- 13 sites in United States, Canada
- Volunteers
- 552 people
- Sponsor
- Arbor Research Collaborative for Health
COPD
Change in Task-related Oxygen Uptake After EBV Treatment
Rationale: Bronchoscopic lung volume reduction using endobronchial valves (EBV) has emerged as a viable treatment option for eligible patients with severe emphysema.
- Trial name
- CROCODILE (NCT06702072)
- Testing
- Endobronchial valve treatment
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Advanced Upper Lobe Predominant Emphysema
Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema
The purpose of the study is to evaluate the efficacy and safety of the 20 mL BLVR System in treating patients with advanced upper lobe predominant emphysema.
- Trial name
- NCT00716053
- Testing
- BLVR
- Volunteers
- 225 people
- Sponsor
- Aeris Therapeutics
Emphysema or COPD
Chartis Collateral Ventilation Measurement: Conscious Sedation Versus General Anesthesia
Rationale: The Chartis® ( Pulmonx, CA, USA) measurement system is a tool to assess interlobar collateral ventilation during bronchoscopy.
- Trial name
- NCT03205826
- Testing
- Type of sedation used
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Comparison of Two Programs to Encourage Physical Activity in Individuals With Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease. Symptoms include shortness of breath, wheezing, and difficulty exercising.
- Trial name
- NCT00328484
- Testing
- Lifestyle Activity Program, Exercise Program
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Heterogeneous Emphysema
Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures
This clinical trial evaluates the impact of catheter-based measurement of interloabr collateral ventilation prior to endoscopic lung volume reduction in patients with hetereogeneous emphysema and complete interlobar fissures in…
- Trial name
- NCT01902732
- Testing
- Implantation of valves (IBV)
- Where
- 5 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
This study is evaluating the effectiveness of a dose counter for an inhaler device used to deliver medication to people diagnosed with asthma or COPD.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT01302587
- Testing
- Albuterol
- Where
- 25 sites in United States
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pneumothorax, Pulmonary Interstitial Emphysema
Surfactant Administration During Spontaneous Breathing
Spontaneous breathing supported by nasal continuous positive airway pressure (nCPAP) is thought to have some advantages compared with mechanical ventilation in premature infants.
- Conditions
- Pneumothorax, Pulmonary Interstitial Emphysema, Bronchopulmonary Dysplasia
- Trial name
- TAKE CARE (NCT01329432)
- Testing
- Take care, InSurE
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Diabetes Mellitus, Type 1
A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II
Aralast NP (alpha-1 antitrypsin, AAT), an alpha-1 proteinase inhibitor (human), was the drug to be tested in this clinical trial.
- Trial name
- RETAIN (NCT01183455)
- Testing
- Aralast NP
- Where
- 15 sites in United States
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)